GenomOncology
GenomOncology is a precision medicine software company founded in Westlake, Ohio, focused on translating complex genomic data into actionable clinical insights for cancer care.
Profile
Software that helps doctors match cancer patients to treatments based on their tumor's genetic profile.
GenomOncology is a precision medicine software company founded in Westlake, Ohio, focused on translating complex genomic data into actionable clinical insights for cancer care. The company emerged from a 2014 collaboration with Vanderbilt-Ingram Cancer Center to commercialize decision support tools based on the My Cancer Genome platform, which matches tumor mutations to therapies. GenomOncology's core offering is its Precision Oncology Platform (POP), which integrates proprietary and licensed datasets to automate variant interpretation and clinical trial matching.
Key products include GO Clinical Workbench for molecular pathologists and GenomAnalytics for researchers. The company has demonstrated traction with academic medical centers and advocacy groups, notably increasing the Pancreatic Cancer Action Network's biomarker-driven trial matching by 300% in 2021. A 2024 partnership with Genomenon enhanced germline variant classification capabilities. While financials are undisclosed, strategic collaborations with Vanderbilt, PanCAN, and Genomenon suggest a focus on leveraging curated oncology knowledge bases rather than proprietary sequencing technology.
Who buys this
- Molecular pathology labs
- Oncology clinics and hospitals
- Cancer research centers
- Patient advocacy organizations
- Pharmaceutical clinical trial teams
Publicly disclosed clients
- Vanderbilt-Ingram Cancer Center
- Pancreatic Cancer Action Network (PanCAN)
Strengths and what to watch
Strengths
- Exclusive commercial license to Vanderbilt's My Cancer Genome knowledge base since 2014
- Proven 300% increase in clinical trial matching efficiency for PanCAN per 2021 case study
- Integrated germline variant classification via 2024 Genomenon partnership
Watch for
- Dependence on Vanderbilt partnership for core IP - no visible renewal since 2014 deal
- Limited public financial disclosures or funding rounds since founding
- Competition from EHR-integrated tools like Epic's Genomics Module
Key Information
- Founded
- 2014
- Headquarters
- Westlake, Ohio
Frequently Asked Questions
What does GenomOncology do?
GenomOncology develops precision medicine software that analyzes tumor genetic profiles to match cancer patients with targeted treatments. Their platform integrates genomic data with clinical insights, helping doctors and researchers identify optimal therapies and clinical trials based on a patient's specific cancer mutations. (42 words)
How does GenomOncology's software improve cancer care?
The Precision Oncology Platform automates interpretation of complex genomic data, enabling faster treatment decisions. Case studies show 300% improvement in matching patients to biomarker-driven trials. It combines proprietary algorithms with licensed datasets like Vanderbilt's My Cancer Genome knowledge base. (43 words)
What is GenomOncology's relationship with Vanderbilt?
Since 2014, GenomOncology has held an exclusive commercial license to Vanderbilt-Ingram Cancer Center's My Cancer Genome platform. This partnership provides access to curated oncology knowledge used in their decision-support tools for molecular pathologists and oncologists. (44 words)
Which organizations use GenomOncology's platform?
Key clients include academic medical centers like Vanderbilt, advocacy groups such as Pancreatic Cancer Action Network, and research institutions. PanCAN reported tripling trial matching efficiency using GenomOncology's biomarker analysis tools. Pharmaceutical teams also utilize it for trial recruitment. (45 words)
What's new in GenomOncology's 2024 partnership?
The Genomenon collaboration enhances germline variant classification capabilities, expanding the platform's ability to interpret inherited cancer risk factors alongside tumor mutations. This strengthens comprehensive genomic profiling for precision treatment recommendations. (40 words)
How does GenomOncology compare to EHR genomics tools?
Unlike EHR-integrated solutions, GenomOncology specializes in curated oncology knowledge bases rather than general sequencing tech. Its niche focus on cancer-specific variant interpretation and partnerships with research institutions differentiate its clinical decision support offerings. (42 words)
Sources
- www.prnewswire.com — 2014 Vanderbilt partnership and My Cancer Genome licensing
- www.prnewswire.com — PanCAN case study showing 300% trial matching improvement
- www.prnewswire.com — 2024 Genomenon partnership for germline data
- www.genomoncology.com — Current product offerings and positioning